Condition
Obesity
Locations
Not recruiting
Start date
09/06/2026
Identifiers
Trial ID NN9662-8649,
NCT number NCT07639021,
Eudract number Not Available
NCT number NCT07639021,
Eudract number Not Available
Summary
The purpose of the study is to find out if NNC0662-0419 is safe and effective for treating participants living with obesity.
Trial Overview:
Treatment
DRUG: NNC0662-0419
DRUG: Semaglutide
DRUG: NNC0662-0419 Placebo
DRUG: Semaglutide placebo
Study type
INTERVENTIONAL
Trial duration
Jun 09 2026 - Jul 12 2027
Participants
230
Phase
II
Are you eligible?
Gender
Male and female
Age
18 years and older
Find out how you can participate
Questions or concerns
Do you have any question about what it’s like being a clinical volunteer? Have a look at our answers to frequently asked questions.
This site contains information about clinical trials sponsored by Novo Nordisk. It is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. The information on this site should not be relied on as the basis for any decision or action. Only a physician can determine whether a specific product is correct for a particular patient. If you have questions regarding any information contained on this site you should consult a physician.